ONLINE SUPPLEMENT

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate

Donald A. Mahler, MD1 Jill A. Ohar, MD2 Chris N. Barnes, PhD3 Edmund J. Moran, PhD3 Srikanth Pendyala, MD3 Glenn D. Crater, MD3

1Geisel School of Medicine at Dartmouth, Hanover, New Hampshire and Respiratory Services, Valley Regional Hospital, Claremont, New Hampshire

2Wake Forest University Medical Center, Winston-Salem, North Carolina

3Theravance Biopharma US, Inc., South San Francisco, California

Methods

Randomization and Treatment Allocation

After screening, eligible patients were randomized to 1 of 2 treatment groups using Interactive Web Response System (Day 1/Visit 2) with the following stratification factors: baseline peak inspiratory flow rate (<40 L/min and ≥40 L/min) against the resistance of Diskus; long-acting β-agonist use; and Global Initiative for Chronic Obstructive Lung Disease airway limitation grade (2, 3, and 4). Randomization was allocated centrally with blocking at the study site level.
*PIFR measured using In-Check device at both resistances set to Diskus and Handihaler (for descriptive purposes)

AE = adverse event; IPR = ipratropium; MIP = maximal inspiratory pressure; PIFR = peak inspiratory flow rate